The Global Measles, Mumps, and Rubella (MMR) Vaccine Market is valued at USD 723.90 Million in 2021 and is expected to reach USD 946.21 Million Billion by 2028 with a CAGR of 3.9% over the forecast period.
Global Measles, Mumps, and Rubella Vaccine (MMR) Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028- Rising cases of Measles, mumps, and rubella, rising number of government initiatives for the development of vaccines as well as growing investment in research and development are some of the major factors driving the growth of the Global Measles, Mumps, and Rubella (MMR) Vaccine Market.
The measles, mumps, and rubella (MMR) vaccine is to protect people from measles, mumps, and rubella. The disease spreads through direct contact with the sneezes or cough drops of a person with the virus. Living viruses are inactive and unable to replicate in human cells when the immune system responds and protects against infection. Measles has a virus which can lead to serious complications, especially in those with a weakened immune system. Additionally, mumps mainly affects the glands. Symptoms include swelling of the salivary glands in the neck, fever, headache, and muscle aches, and rubella is a viral infection. It causes mild fever and rash in infants and children. Thus, to prevent birth defects caused by rubella, pregnant women are vaccinated with measles, mumps, and rubella vaccine.
The Covid-19 outbreak has slightly affected the measles, mumps, and rubella virus vaccine market in the year 2020. Due to the strict lockdown measures and social distancing norms across the globe measles, mumps, and rubella vaccine market was affected. Additionally, the unbreakable spread and increasing death rate due to coronavirus, number of pharmaceutical companies are mainly focused on the corona vaccine innovation for conquer the situation, due to that pharmaceutical companies rushed towards the research & development and production of coronavirus vaccine. Similarly, the transportation restrictions are create raw material shortage in manufacturing companies and it somehow impacting on the production of MMR vaccine. Another factor that affected in coronavirus pandemic is less number of childhood vaccinations. For example; according to WHO and UNICEF 23 million children miss out on basic vaccines through routine immunization services in 2020. Despite this, one of the studies found that kids inoculated with the measles vaccine had milder symptoms upon contracting the novel coronavirus than those not vaccinated. The measles vaccine is 87.5 percent effective against coronavirus in children and can provide long-term protection against the virus.
The global measles, mumps, and rubella vaccine market is segmented based on age group, distribution channel, and region & country level. Based on the age group, the global measles, mumps, and rubella (MMR) vaccine market is segmented into pediatric and adult. Based on distribution channel, the measles, mumps, and rubella (MMR) vaccine market is segmented into hospitals pharmacies, drug stores, and retail pharmacies.
The regions covered in this global measles, mumps, and rubella (MMR) vaccine market report are Asia-Pacific, North America, Europe, and the Rest of the World. Based on a country level, the market of global measles, mumps, and rubella (MMR) vaccine is subdivided into the U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, Southeast Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.
The Global Measles, Mumps, And Rubella (MMR) vaccine Market report cover the key players are
On August 3rd, 2021; South African scientists launched a clinical trial to test whether the childhood vaccine for measles, mumps and rubella (MMR) can protect frontline healthcare workers from Covid-19 or reduce the severity of illness for those who become infected. The trials were launched by the South African scientists from the Universities of the Cape Town (UCT) and University of the Witwatersrand.
On August 2nd, 2021; GSK submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for PRIORIX (Measles, Mumps, and Rubella Virus Vaccine, Live) and is seeking approval for use in active immunization against infection by measles, mumps and rubella (MMR).
Rising cases of measles, mumps, and rubella disease is one of the major factors driving the growth of global measles, mumps, and rubella (MMR) vaccine market. Measles is a contagious disease that causes fever, a red rash, cough and red eyes. It can have serious complications such as encephalitis, which itself can cause hearing loss. For example; in 2018; 17 822 cases of measles were reported by 29 EU/EEA Member States. During, 2016, Global measles deaths climbed nearly 50 percent since 2016, claiming an estimated 207 500 lives in 2019 alone. Additionally, Mumps is a viral infection that mainly affects the salivary glands near your ears. Mumps can cause swelling of one or both of these glands. Mumps was common in the United States until mumps vaccination became routine. Since then, the number of cases has dropped dramatically. For example, Mumps occurs worldwide, with 500,000 cases reported on average annually. Similarly, rubella is also one of the major infectious diseases which mostly detect into the children’s. Rubella can cause a miscarriage or serious birth defects in a developing baby if a woman is infected while she is pregnant. For the protection against rubella is MMR (measles-mumps-rubella) vaccine. For example; each year about 100,000 cases of congenital rubella syndrome occur.
In addition, rising number of government initiatives for the development of vaccines as well as growing investment in research and development are also supplementing the market growth. The increasing spread of the MMR virus outbreak is creating a huge burden on the health department in globally. To avoid these infectious diseases government taking various types of initiative like, they ran a campaign for vaccination. By vaccination campaign governments are try to increase awareness about MMR vaccine and immune population. For example; Indian government ran MR campaign which is about Measles and rubella campaign. In this, the governments are trying to cover at least 95% coverage will ensure population immunity.
Additionally, MMR vaccine is being introduced through a campaign and will be simultaneously introduced in the routine program by replacing measles vaccine currently administered under national immunization. Moreover, growing investments by pharmaceutical companies in this field is also supplementing the market growth.However, high cost required vaccine development may hamper the market growth. Despite this, increasing research and development activities in this field may create more opportunities for the further growth of the market.
Geographically, North America is expected to dominate the global Measles, Mumps, and Rubella (MMR) vaccine market. The huge presence of pharmaceutical companies has made it easier to manufacture a number of MMR vaccines in the same way, various companies are seeking FDA permission for their vaccines, highly developed healthcare infrastructure and high awareness in this region. According to the US vaccination schedule, people who receive the MMR vaccine are generally considered lifelong protected from measles and rubella. In 2019, a total of 1,242 temporary cases of measles were reported to the CDC from 31 states. Despite of in North America MMR vaccination rate is very high due to the people awareness and government initiative. For example; in New York City from March to May 2020, there was an 82 percent decrease in the number of MMR (measles, mumps and rubella) vaccine doses administered to children 2-8 years compared to the same months in 2018 and 2019
Asia Pacific is expected to show a significant growth in the global Measles, Mumps and Rubella (MMR) vaccine market. The increasing number of infectious diseases into paediatric population is boosting the growth of market in this region. Additionally, measles is a highly contagious viral disease that initially infects the respiratory tract and then spreads throughout the body. It is transmitted through the mouth, nose or throat of an infected person. Rubella is also a highly contagious viral infection. If the virus is found during pregnancy, the baby may have a birth defect or even fetal death. Both measles and rubella are usually accompanied by other symptoms, including fever and acne. For example; China is the top country by rubella cases in the world. As of 2020, rubella cases in China were 2,202 that accounts for 21.60% of the world's rubella cases. To conquer the side effects related to MMR disease various countries governments are increasingly focused on the vaccinations related to MMR disease. Moreover, India, along with ten other member countries of the WHO Southeast Asia region, is committed to control measles and rubella / congenital rubella syndrome (CRS) by 2020. In this direction, the Ministry of Health and Family Welfare has started measles-rubella (MR). Vaccination campaigns across the country for 9 months to 15 years of age in phases. The campaign aims to involve about 41 crore children. Over 34 million children aged 9 months to 9 years old will be vaccinated against measles and rubella (MR) in a massive 6-week-long campaign beginning today all over the country.
Middle East and Africa
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2028|
|Market Size in 2021:||USD 723.90|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD 946.21 Million|
|Tables, Charts & Figures:||175|
|Measles, mumps, and rubella vaccine Companies||MedImmune, Johnson & Johnson Private Limited, Merck & Co., Inc., Sanofi, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Astellas Pharma India Private Limited, CSL Limited, Emergent BioSolutions Inc., and GlaxoSmithKline plc. and others.|
|Segments Covered||By Vaccine Type, By Disease Type, By Age Group, By Distribution Channel|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|